SYNERGY™ & SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY™ Stent Safety in Real-World SCAAR Registry

SYNERGY BP Stent showed numerically lowest ST rates compared to other DES despite being used in patients with more complex disease

SYNERGY™ Stent Safety: ST rates in real-world SCAAR registry1
  SYNERGY Stent DES p
N patients

4,247

38,110

<0.01

Class B2/C Lesions

59%

54%

<0.01

LM

6.9%

6.1%

NS

CTO

4.8%

4.1%

NS

2VD

30.0%

29.4%

NS

Diabetes

23.1%

21.9%

<0.01

Prior PCI

31.2%

29.2%

<0.01

3VD

17.4%

16.6%

<0.01

Stent Diameter

2.95 mm

3.00 mm

<0.01

Stent Length

22.32 mm

20.32 mm

<0.01

A total of 7,886 of Synergy stents and 64,429 other n-DES (BioMatrix, N= 1,953; Orsiro, N= 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7,971, Resolute/Resolute Integrity, N=19,021; Ultimaster, N= 1,156; Resolute Onyx, N= 6,425) were implanted in 42,357 procedures.
 

SYNERGY BP Stent showed numerically lowest ST rates compared to other new-generation DES despite use in more complex patients with AMI

ST rates in SCAAR AMI Subset2
Definite Stent Thrombosis
SCAAR: Definite Stent Thrombosis
  SYNERGY BP Stent n-DES p
N patients

4,889

31,403

 

Previous MI

24.6%

22.1%

<0.001

Previous PCI

21.9%

19.3%

<0.001

Left Main

5.5%

4.8%

0.026

3VD

25.1%

22.2%

<0.001

Restenotic lesion

6.3%

4.8%

<0.001

Multivessel PCI

23.9%

20.7%

<0.001

 

SYNERGY Stent demonstrated the lowest ST rates in patients with ACS

ST rates in real-world SCAAR registry3
ACS Subset
 
Optimal Healing

Optimal Healing

Advanced design for optimal healing

Button
Clinical Program

Clinical Program

Addressing the full spectrum of cardiovascular disease complexity

Button
Top